Additionally, the ReDisX framework suggests the specific drug designated for a subpopulation of RA patients with GZMB under-expression can be repurposed for the subpopulation of CAD patients having GZMB under-expression but never be used for the subpopulation of RA patients with GZMB overexpression. This evidence concerns the gene GZMB and coronary artery disorder.